These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19566124)

  • 21. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS; Stoeltzing O; Ellis LM
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.
    Hassan S; Buchanan M; Jahan K; Aguilar-Mahecha A; Gaboury L; Muller WJ; Alsawafi Y; Mourskaia AA; Siegel PM; Salvucci O; Basik M
    Int J Cancer; 2011 Jul; 129(1):225-32. PubMed ID: 20830712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
    Kong DH; Kim MR; Jang JH; Na HJ; Lee S
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The VEGF family in cancer and antibody-based strategies for their inhibition.
    Sullivan LA; Brekken RA
    MAbs; 2010; 2(2):165-75. PubMed ID: 20190566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of nanoparticulate delivery systems in metronomic chemotherapy.
    Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
    Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies.
    Darvishi B; Majidzadeh-A K; Ghadirian R; Mosayebzadeh M; Farahmand L
    Life Sci; 2019 Jan; 217():34-40. PubMed ID: 30472294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
    Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
    Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mathematical modeling in scheduling cancer treatment with combination of VEGF inhibitor and chemotherapy drugs.
    Lai X; Friedman A
    J Theor Biol; 2019 Feb; 462():490-498. PubMed ID: 30468760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mathematical modelling of tumour angiogenesis and invasion.
    Chaplain MA
    Acta Biotheor; 1995 Dec; 43(4):387-402. PubMed ID: 8919350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer.
    De Souza R; Zahedi P; Moriyama EH; Allen CJ; Wilson BC; Piquette-Miller M
    Mol Cancer Ther; 2010 Jun; 9(6):1820-30. PubMed ID: 20530719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
    Niu G; Chen X
    Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of angiogenesis and tumor growth by a novel 1,4-naphthoquinone derivative.
    Murota H; Shinya T; Nishiuchi A; Sakanaka M; Toda KI; Ogata T; Hayama N; Kimachi T; Takahashi S
    Drug Dev Res; 2019 May; 80(3):395-402. PubMed ID: 30632632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
    Rosen LS
    Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.
    Kazemi-Lomedasht F; Behdani M; Bagheri KP; Habibi-Anbouhi M; Abolhassani M; Arezumand R; Shahbazzadeh D; Mirzahoseini H
    Mol Immunol; 2015 May; 65(1):58-67. PubMed ID: 25645505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
    Shojaei F; Wu X; Qu X; Kowanetz M; Yu L; Tan M; Meng YG; Ferrara N
    Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6742-7. PubMed ID: 19346489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method.
    Kassara K; Moustafid A
    Math Biosci; 2011 Jun; 231(2):135-43. PubMed ID: 21377480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.
    Alishekevitz D; Bril R; Loven D; Miller V; Voloshin T; Gingis-Velistki S; Fremder E; Scherer SJ; Shaked Y
    Mol Cancer Ther; 2014 Jan; 13(1):202-13. PubMed ID: 24150126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.